{"type":"trials","record":{"id":41635,"source_id":"clinicaltrials-gov","external_id":"NCT04437368","title":"EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005","brief_summary":"The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).","overall_status":"Terminated","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Gyroscope Therapeutics Limited","enrollment":98,"countries":["United States","Australia","France","Germany","Netherlands","Poland","Spain","United Kingdom"],"start_date":"2019-04-26","completion_date":"2024-04-05","last_update_date":"2026-01-27","source_url":"https://clinicaltrials.gov/study/NCT04437368","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"EXPLORE","age_range":"55 Years","comparator":"Untreated control","organization":"Gyroscope Therapeutics Limited","interventions":["GT005"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The Change From Baseline to Week 48 in Geographic Atrophy (GA) - Part 1 — Baseline, Weeks 12, 24, 36, and 48","The Change From Baseline in Geographic Atrophy (GA) at Week 72 and Week 96 - Part 1 — Baseline, Weeks 72 and 96","Summary of Adverse Events - Parts 1 and 2 Combined — Adverse events are reported from randomization up to end of study,…","Ocular Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye - Parts 1 and 2 Combined — Adv…","Non-ocular Adverse Events - Summary - Parts 1 and 2 Combined — Adverse events are reported from randomization up to end…","Change in GA Morphology From Baseline to Week 96 on Colour Fundus Photography (CFP) - Number of Participants With Incre…","Change From Baseline to Week 48 in GA Morphology on Colour Fundus Photography (CFP) - Number of Participants With Incre…","Change in Best Corrected Visual Acuity (BCVA) Score From Baseline Through Week 96 Via the Early Treatment for Diabetic…","Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, 48, 72 and 96, Via Early Treat…","Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, and 48, Via Early Treatment fo…","Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Reading Performance, Measured as the Maximum Reading Speed (Word…","Change From Baseline at Weeks 24, 36 and 48 in Reading Performance, Measured as the Maximum Reading Speed (Words Per Mi…","Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Functional Reading Independence (FRI) Index - Part 1 — Baseline,…","Change From Baseline at Weeks 24, 36 and 48 in Functional Reading Independence (FRI) Index - Part 2 — Baseline, Weeks 2…","Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Patient Reported Outcomes (Visual Function Questionnaire-25) - C…","Change From Baseline at Weeks 24, 36 and 48 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Composite…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Dry Age-related Macular Degeneration","GT005"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04437368","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-04-26 to 2024-04-05","comparator":"Untreated control","confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.845Z","intervention":["GT005"],"participants":98,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The Change From Baseline to Week 48 in Geographic Atrophy (GA) - Part 1 — Baseline, Weeks 12, 24, 36, and 48","The Change From Baseline in Geographic Atrophy (GA) at Week 72 and Week 96 - Part 1 — Baseline, Weeks 72 and 96","Summary of Adverse Events - Parts 1 and 2 Combined — Adverse events are reported from randomization up to end of study,…","Ocular Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye - Parts 1 and 2 Combined — Adv…","Non-ocular Adverse Events - Summary - Parts 1 and 2 Combined — Adverse events are reported from randomization up to end…","Change in GA Morphology From Baseline to Week 96 on Colour Fundus Photography (CFP) - Number of Participants With Incre…","Change From Baseline to Week 48 in GA Morphology on Colour Fundus Photography (CFP) - Number of Participants With Incre…","Change in Best Corrected Visual Acuity (BCVA) Score From Baseline Through Week 96 Via the Early Treatment for Diabetic…","Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, 48, 72 and 96, Via Early Treat…","Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, and 48, Via Early Treatment fo…","Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Reading Performance, Measured as the Maximum Reading Speed (Word…","Change From Baseline at Weeks 24, 36 and 48 in Reading Performance, Measured as the Maximum Reading Speed (Words Per Mi…","Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Functional Reading Independence (FRI) Index - Part 1 — Baseline,…","Change From Baseline at Weeks 24, 36 and 48 in Functional Reading Independence (FRI) Index - Part 2 — Baseline, Weeks 2…","Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Patient Reported Outcomes (Visual Function Questionnaire-25) - C…","Change From Baseline at Weeks 24, 36 and 48 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Composite…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41635","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}